Top 5 Radiotherapy Companies
GE Healthcare
Accuray
Siemens Healthineers
IsoRay
Elekta
Source: Mordor Intelligence
Radiotherapy Companies Matrix by Mordor Intelligence
Our comprehensive proprietary performance metrics of key Radiotherapy players beyond traditional revenue and ranking measures
The MI Matrix can diverge from revenue rank because it weights what buyers feel day to day. Installed base reach, service uptime, and the ability to implement upgrades often matter as much as new system sales. Innovation also changes the picture when new workflows, like adaptive planning, shift purchasing toward software and integration partners. Operational depth, such as commissioning capacity and field engineer coverage, can move a company up even when equipment shipments are uneven. Radiotherapy equipment typically includes linear accelerators, brachytherapy afterloaders, particle therapy systems, and the software that plans and verifies dose. MR Linac systems combine MRI with a linac so teams can see soft tissue during treatment and adapt the plan before delivery. This MI Matrix by Mordor Intelligence is better for supplier and competitor evaluation than revenue tables alone because it reflects readiness to deliver reliable outcomes across sites, not just sales totals.
MI Competitive Matrix for Radiotherapy
The MI Matrix benchmarks top Radiotherapy Companies on dual axes of Impact and Execution Scale.
Analysis of Radiotherapy Companies and Quadrants in the MI Competitive Matrix
Comprehensive positioning breakdown
Siemens Healthineers
FDA clearance for Varian's HyperSight imaging on TrueBeam and Edge signals continued momentum in image guidance and adaptive workflows. Siemens Healthineers, a leading company in radiation oncology, can still face procurement friction when policy scrutiny slows hospital ordering in large countries, which can reshape near term installation timing. If reimbursement rises for hypofractionation, Siemens can pull demand toward higher throughput linacs and software upgrades. A practical risk is delayed parts availability for complex imaging chains, which can stretch acceptance testing and service response times.
Elekta AB
Clinical adoption keeps tilting toward MR guided adaptive treatment, which favors platforms that simplify daily decision making. Elekta, a major player, reinforced this position through a 2025 collaboration with Moffitt built around Unity MR Linac and associated software and service scope. If staffing shortages deepen, Elekta benefits when centers prioritize automation and repeatable workflows over feature breadth. The main operational risk is extended on site training time for MR guided routines, which can slow ramp up and create uneven utilization across shifts.
Ion Beam Applications SA
Proton system economics are improving, yet conversion discipline still separates winners from hopeful entrants. One leading vendor reported FY2024 results showing higher net sales and a return to profitability, supported by backlog conversion and margin improvement. If more hospitals choose phased proton expansion, IBA is positioned to package equipment, lifecycle service, and clinical tooling into tighter delivery schedules. A key risk is execution complexity on older projects where contract terms were set before today's cost inflation, which can compress margins.
Hitachi Ltd.
New proton awards remain a strong proxy for credibility because centers rarely switch vendors mid project. Hitachi, a top conglomerate, secured a 2025 order for a proton therapy system in Tokyo that includes accelerator and rotating gantry rooms. If national cancer plans expand particle therapy capacity, Hitachi can benefit from turnkey delivery plus long term maintenance. The key risk is long construction timelines that push acceptance milestones far into the future, which raises exposure to schedule slips and evolving safety requirements.
RaySearch Laboratories AB
Planning platforms are increasingly judged on adaptive speed, robustness, and ability to support multiple modalities in one clinic. RaySearch, a top player in treatment planning, reported 2024 results showing higher net sales, improved operating profit, and order intake growth, which signals durable demand for RayStation and related systems. If adaptive planning becomes standard for more disease sites, RaySearch can expand footprint without owning the linac. A core risk is reliance on partner delivery systems and local regulatory pathways, which can delay deployments in certain countries.
Frequently Asked Questions
What should a hospital verify before buying a linac or radiosurgery system?
Confirm regulatory clearance for the configuration you will use, not a similar model. Require a written commissioning plan, staffing plan, and a parts availability commitment for the full service term.
How should a center compare photon therapy versus proton therapy for a new site?
Start with case mix, referral stability, and the building timeline. Proton projects also need stronger construction governance because schedule risk can outweigh the clinical plan.
What questions best predict service performance after go live?
Ask for local field engineer coverage, typical response time, and parts stocking strategy. Also ask how software updates are tested and rolled out without interrupting patient schedules.
When does MR guided adaptive radiotherapy make operational sense?
It tends to fit best when daily adaptation replaces re simulation and reduces margin expansions. It can strain throughput at first, so staffing and training plans must be realistic.
What are practical red flags in treatment planning software selection?
Limited interoperability with existing record and verify systems is a major risk. Another red flag is a weak upgrade path for adaptive workflows and automated contouring.
How can buyers reduce commissioning and acceptance testing delays?
Lock room readiness criteria early, including shielding, power quality, and network security approvals. Align vendor and physics team calendars before equipment delivery is scheduled.
Methodology
Research approach and analytical framework
Data sourcing prioritizes company investor materials, regulatory filings, and standards bodies, then credible journalism. Public and private firms are scored using observable signals like clearances, contracts, and site activity. When direct figures are limited, multiple indicators are triangulated to avoid single source bias.
More installed systems and service hubs reduce downtime risk for hospitals and centers across regions.
Trusted names shorten tender cycles and increase clinician confidence in plan quality and safety processes.
Proxy for how often a vendor is selected for linacs, particle systems, planning, and service renewals.
Commissioning teams, parts logistics, and training capacity determine how fast a site reaches full throughput.
Adaptive planning, MR guidance, biology guided delivery, and QA automation since 2023 drive upgrade and replacement decisions.
Stable cash generation supports spares, software roadmaps, and multi year service commitments for high uptime care.
